dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
The Aviation Safety Reporting System (ASRS) collects voluntarily submitted aviation safety incident/situation reports from pilots, controllers and others. The ASRS uses reports to identify system deficiencies, issue alert messages, and produce two publications, CALLBACK, and ASRS Directline. The collected information is made available to the public, and is used by the FAA, NASA and other organizations working in research and flight safety.
Alternative splicing is one of the most important components that show functional complexity of genome. Modified splicing has significant effect on the phenotype that is relevance to disease or drug metabolism. A change in splicing can be caused by modifying any of the components of the splicing machinery such as splice sites or splice enhancers or silencers. Modification in the alternative splicing site can lead to a different protein form which will show a different function. Humans use an estimated 100,000 different proteins or more, so some genes must be capable of coding for a lot more than just one protein. Alternative splicing occurs more frequently than was previously thought and can be hard to control; genes may produce tens of thousands of different transcripts, necessitating a new gene model for each alternative splice.
A blood glucose meter is an electronic device for measuring the blood glucose level. A relatively small drop of blood is placed on a disposable test strip which interfaces with a digital meter. Within several seconds, the level of blood glucose will be shown on the digital display. Needing only a small drop of blood for the meter means that the time and effort required for testing are reduced and the compliance of diabetic people to their testing regimens is improved significantly. Blood glucose meters provide results in various units such as eAG (mg/dL) and eAG (mmol/L), and may also estimate A1C levels. These measurements can aid in classifying blood glucose levels as normal, prediabetic, or diabetic, facilitating effective diabetes management for users. While some models offer interpretative features that indicate the health status based on these results, not all meters provide this functionality, focusing instead on providing raw glucose measurements. Users of blood glucose meters without interpretative features can utilize online calculators to determine their blood glucose status based on measured values. The cost of using blood glucose meters is believed to be a cost-benefit relative to the avoided medical costs of the complications of diabetes. Recent advances include:
Sources: en.wikipedia.org
GLP-1 analogs resulted in weight loss and had more gastrointestinal side-effects, while in general dipeptidyl peptidase-4 (DPP-4) inhibitors were weight-neutral and are associated with increased risk for infection and headache. Both classes appear to present an alternative to other antidiabetic drugs. However, weight gain and/or hypoglycemia have been observed when dipeptidyl peptidase-4 inhibitors were used with sulfonylureas; effects on long-term health and morbidity rates are still unknown. DPP-4 inhibitors increase blood concentration of the incretin GLP-1 by inhibiting its degradation by DPP-4. Examples are:
====== Order Proboscidea ====== Family Elephantidae (Elephants) Elephas maximus, Asian elephant, (2015, 2024) † Mammuthus primigenius, Wooly mammoth, (2015) Loxodonta africana, African bush elephant, (2009, 2024) Loxodonta cyclotis, African forest elephant, (2018)
== Diagnosis == The diagnosis of nipple pain in breastfeeding can be divided into three major parts: the measurement of pain intensity, a physical examination on the breastfeeding mother and the infant to identify the cause of pain and the study of the psychological impact of pain in the breastfeeding woman.
Sources: en.wikipedia.org
1950s: Chinese-American medical scientist Tsai-Fan Yu co-founded a clinic at Mount Sinai Medical Center for the study and treatment of gout. Working with Alexander B. Gutman, Yu established that levels of uric acid were a factor in the pain experienced by gout patients, and subsequently developed multiple effective drugs for the treatment of gout. 1950: Chinese-American particle physicist Chien-Shiung Wu proved the validity of Quantum entanglement which counters Albert Einstein's EPR Paradox and published her work on the new year of the new decade. She also proved the validity of beta decay around this time. 1950: Ghanaian physician and science educator Matilda J. Clerk became the first woman in Ghana and West Africa to attend graduate school, earning a postgraduate diploma at the London School of Hygiene & Tropical Medicine. 1950: Isabella Abbott became the first Native Hawaiian woman to receive a PhD in any science; hers was in botany. 1950: American microbiologist Esther Lederberg became the first to isolate lambda bacteriophage, a DNA virus, from Escherichia coli K-12. 1951: American oncologist Jane C. Wright was the first to identify methotrexate, one of the foundational chemotherapy drugs, as an effective tool against cancerous tumors. 1951: Ghana's Esther Afua Ocloo became the first person of African ancestry to obtain a cooking diploma from the Good Housekeeping Institute in London and to take the post-graduate Food Preservation Course at Long Ashton Research Station, Department of Horticulture, Bristol University.
The Workers Party of Bangladesh (reconstituted) was a political party in Bangladesh. Haider Akbar Khan Rano was the convenor of the party. Rano had led a group of dissident leaders of the Workers Party of Bangladesh, who had broken away from WPB in connection with the December 2008 parliamentary election. Rano's group, which formed the WPB(reconstituted) opposed the alliance between the Workers Party and the Awami League and the participation of WPB candidates in the election on the Awami League election symbol. In September 2009 Abdul Matin, a hero of the Language movement, joined the party. Matin was included in the Central Committee of the party. Afterwards he joined to the party United Communist League of Bangladesh. On 26 February 2010, the Workers Party of Bangladesh (reconstituted) merged into the Communist Party of Bangladesh. Haider Akbar Khan Rano was included in the presidium of CPB and Mohamed Habibur Rahman and Shahrier Mohammad Firoj were appointed Central Committee members of CPB.
The human heart is situated in the mediastinum, at the level of thoracic vertebrae T5–T8. A double-membraned sac called the pericardium surrounds the heart and attaches to the mediastinum. The back surface of the heart lies near the vertebral column, and the front surface, known as the sternocostal surface, sits behind the sternum and rib cartilages. The upper part of the heart is the attachment point for several large blood vessels—the venae cavae, aorta and pulmonary trunk. The upper part of the heart is located at the level of the third costal cartilage. The lower tip of the heart, the apex, lies to the left of the sternum (8 to 9 cm from the midsternal line) between the junction of the fourth and fifth ribs near their articulation with the costal cartilages. The largest part of the heart is usually slightly offset to the left side of the chest (levocardia). In a rare congenital disorder (dextrocardia) the heart is offset to the right side and is felt to be on the left because the left heart is stronger and larger, since it pumps to all body parts. Because the heart is between the lungs, the left lung is smaller than the right lung and has a cardiac notch in its border to accommodate the heart. The heart is cone-shaped, with its base positioned upwards and tapering down to the apex. An adult heart has a mass of 250–350 grams (9–12 oz). The heart is often described as the size of a fist: 12 cm (5 in) in length, 8 cm (3.5 in) wide, and 6 cm (2.5 in) in thickness, although this description is disputed, as the heart is likely to be slightly larger.
First, 2-chloro-6-methoxy-3-nitropyridine and 2-aminopropane-1,3-diol undergo nucleophilic aromatic substitution (SNAr) to form a diol, which is then protected by 2,2-dimethoxypropane to form a ketal intermediate. The intermediate is reduced with hydrogen catalyzed by Pd/C to afford an amine, which then immediately goes through substitution with ethyl bromoacetate. The resulting compound is treated with NaH, and is then oxidized with MnO2 to form the pyrazinone ring. The ketal is deprotected with aqueous HCl to regenerate the diol, and is then treated with methanesulfonic anhydride and triethylamine to form the final ring of the tricyclic core. The resulting compound goes through substitution with tert-butyl piperidin-4-ylcarbamate, acidic deprotection of the amino group, and chiral preparative HPLC to give the enantio-pure penultimate amine intermediate. Finally, a reductive amination is performed, and the product is treated with HCl in diethyl ether to form gepotidacin as a hydrochloride. This route consists of 11 steps, with 8 steps aimed at the formation of the tricyclic core.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.